Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the international radioimmunotherapy network.

Details

Serval ID
serval:BIB_954B2D965E56
Type
Article: article from journal or magazin.
Collection
Publications
Title
Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the international radioimmunotherapy network.
Journal
Journal of Nuclear Medicine
Author(s)
Hohloch K., Delaloye A.B., Windemuth-Kieselbach C., Gómez-Codina J., Linkesch W., Jurczak W., Cacchione R., Suh C., Zinzani P.L., Trümper L.
ISSN
1535-5667 (Electronic)
ISSN-L
0161-5505
Publication state
Published
Issued date
2011
Volume
52
Number
9
Pages
1354-1360
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublish
Abstract
The Radioimmunotherapy Network (RIT-N) is a Web-based, international registry collecting long-term observational data about radioimmunotherapy-treated patients with malignant lymphoma outside randomized clinical studies. The RIT-N collects unbiased data on treatment indications, disease stages, patients' conditions, lymphoma subtypes, and hematologic side effects of radioimmunotherapy treatment. Methods: RIT-N is located at the University of Gottingen, Germany, and collected data from 14 countries. Data were entered by investigators into a Web-based central database managed by an independent clinical research organization. Results: Patients (1,075) were enrolled from December 2006 until November 2009, and 467 patients with an observation time of at least 12 mo were included in the following analysis. Diagnoses were as follows: 58% follicular lymphoma and 42% other B-cell lymphomas. The mean overall survival was 28 mo for follicular lymphoma and 26 mo for other lymphoma subtypes. Hematotoxicity was mild for hemoglobin (World Health Organization grade II), with a median nadir of 10 g/dL, but severe (World Health Organization grade III) for platelets and leukocytes, with a median nadir of 7,000/mu L and 2.2/mu L, respectively. Conclusion: Clinical usage of radioimmunotherapy differs from the labeled indications and can be assessed by this registry, enabling analyses of outcome and toxicity data beyond clinical trials. This analysis proves that radioimmunotherapy in follicular lymphoma and other lymphoma subtypes is a safe and efficient treatment option.
Pubmed
Web of science
Open Access
Yes
Create date
23/09/2011 13:42
Last modification date
08/05/2019 22:16
Usage data